Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma

Patients will receive a PET/MRI scan within 6 weeks of their standard of care imaging. There
is no maximum number of scans for research. The number of scans depends on each patient's
treatment plan.

Inclusion Criteria:

- Presence of suspicious lesion of the pancreas consistent with pancreatic
adenocarcinoma. Cytological confirmation is not required.

- Patients preparing to receive therapy for pancreas cancer, including patients enrolled
in NCT01413022

- Patient must be 18 years or older

- Patient must have a life expectancy of more than 6 months and performance status of 2
or less

- Patient must be able to understand and willing to sign an approved written informed
consent document

- Women of childbearing potential and men must agree to use adequate contraception prior
to study entry and for the length of the study

- Patients enrolled in the Clinical trials.gov# NCT01413022 trial must meet both studies
eligibility criteria.

Exclusion Criteria:

- Patient must not have had prior resection for pancreatic adenocarcinoma.

- Patient must not have a history of other malignancy less than or equal to 5 years
previous with the exception of basal cell or squamous cell carcinoma of the skin which
were treated with local resection only or carcinoma in situ of the cervix

- Patient must not be unable to receive a PET-MRI scan due to renal function, allergy or
other problem with receiving or tolerating an MRI scan, etc. All patients will fill
out a standard MRI screening form.

- Patients must not have a blood glucose of greater than or equal to 200mg/dL at the
time of PET-MRI or if a patient is diabetic and glucose is not controlled. At the
discretion of the PI and the authorized user and with their approval prior to
2-[18]fluoro-2-deoxy-D-glucose (FDG) injection, patients with blood glucose ≥ 200
mg/dL may participate in the study.

- Patient must not be pregnant and/or breast feeding